Isimig

Frovatriptan succinate monohydrate, the active ingredient in Isimig, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults and works by targeting serotonin receptors to relieve headache, nausea, photophobia, and phonophobia.

GNH USA supplies Isimig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality manufacturing, regulatory compliance, and reliable logistics for global distribution.

Isimig (frovatriptan) is used in the acute migraine pathway to abort headache episodes.

Migraine attacks: provides rapid relief of headache, nausea, and sensitivity to light or sound. Migraine with aura: aborts attacks regardless of aura presence. Recurrent episodic migraine: reduces severity of individual attacks when taken at onset.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Fatigue or drowsiness - Nausea or abdominal pain - Dry mouth

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Serotonin syndrome, especially with serotonergic drugs - Severe allergic reactions (anaphylaxis, angioedema) - Hypertension or hypertensive crisis - Persistent visual disturbances

Before initiating therapy, evaluate cardiovascular risk and contraindications.

Assess cardiovascular history: avoid use in patients with coronary artery disease or uncontrolled hypertension. Avoid concomitant triptans: do not combine with other triptan agents. Do not use with ergot derivatives: increased risk of vasospasm. Use caution with serotonergic antidepressants: monitor for serotonin syndrome. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Frovatriptan may interact with several drug classes that affect serotonin pathways or vascular tone.

Major Interactions (Avoid): - Ergot alkaloids: risk of severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): heightened risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Other triptans: additive vasoconstrictive effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase frovatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy of frovatriptan.